Advertisement
Advertisement
XGN
Exagen Inc. Common Stock
2.88
USDSponsored
+0.14
+5.22%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
2.88
0.00
0.00%
XGN Earnings Reports
Positive Surprise Ratio
XGN beat 20 of 26 last estimates.
77%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$16.68M
/-$0.23
Implied change from Q4 25 (Revenue/ EPS)
+0.31%
/+15.00%
Implied change from Q1 25 (Revenue/ EPS)
+7.64%
/+15.00%
Exagen Inc. Common Stock earnings per share and revenue
On Mar 10, 2026, XGN reported earnings of -0.20 USD per share (EPS) for Q4 25, missing the estimate of -0.19 USD, resulting in a -4.22% surprise. Revenue reached 16.63 million, compared to an expected 16.73 million, with a -0.61% difference. The market reacted with a -6.15% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 16.68 million USD, implying an increase of 15.00% EPS, and increase of 0.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
Sanara MedTech Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.11
Actual
$0.04
Surprise
-64.35%
Cytosorbents Corp.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.09
Surprise
-76.47%
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
FAQ
What were Exagen Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Exagen Inc. Common Stock reported EPS of -$0.20, missing estimates by -4.22%, and revenue of $16.63M, -0.61% below expectations.
How did the market react to Exagen Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -6.15%, changed from $6.34 before the earnings release to $5.95 the day after.
When is Exagen Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Exagen Inc. Common Stock's next earnings report?
Based on 9
analysts, Exagen Inc. Common Stock is expected to report EPS of -$0.23 and revenue of $16.68M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement